Trial record 15 of 17 for:    ponatinib

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

This study has been terminated.
(Study terminated based on evaluation of safety data.)
Information provided by (Responsible Party):
Ariad Pharmaceuticals Identifier:
First received: July 18, 2012
Last updated: March 5, 2014
Last verified: March 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: June 2021
  Estimated Primary Completion Date: June 2021 (Final data collection date for primary outcome measure)